Tolerx Diabetes Candidate Falters in Phase III Trial
By Catherine Shaffer
Monday, March 14, 2011
The future of a $760 million partnership between Tolerx Inc. and GlaxoSmithKline plc has been cast into doubt as their investigational humanized anti-CD3 antibody missed its primary endpoint in a Phase III trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.